Overview

In this activity, Dr. Tannir reviews a patient case with metastatic clear-cell RCC and follows the patient through risk stratification and treatment selection. Learners are walked through clinical decisions points regarding diagnostic approaches, risk stratification, selection of therapy, duration of therapy, and role of PD-L1 status. This discussion is supported by relevant clinical trial data and real-world experience.

This activity is intended for medical oncologists, urologist oncologists, surgeons and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.

• Improved knowledge of current mechanisms of action of immunotherapeutic agents and how they apply to the treatment of RCC in terms of rationale. 
• Increased confidence in use of immunotherapies for RCC and utilization of relevant combination regimens in appropriate patients as part of their overall treatment to improve outcomes in patients with RCC.
• Improved understanding of the need to identify the range of irAEs, and improved knowledge of how irAEs differ from side effects associated with traditional chemotherapy.

At the conclusion of this educational activity, the participant should be able to:
• Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies improve treatment of RCC, including combination anti-VEGF and immunotherapeutic platforms (Knowledge, Competence)
• Discuss clinical factors when immunotherapy or combination immunotherapy should be considered as a treatment option for patients with RCC, such as patient selection, optimal drug combinations, and treatment sequence (Knowledge, Competence, Performance)
• Review clinical strategies for the early detection and management of immunotherapy and immunotherapy combination related adverse events in RCC patients and management plans to help mitigate them (Knowledge, Competence, Performance)

Supported by an educational grant from Pfizer and EMD Serono.